Cheapest Semaglutide 2026: $99/mo Trimi vs $1,349/mo Wegovy
Cheapest semaglutide May 2026: Trimi $99/mo annual ($1,188/yr) vs Wegovy ~$1,349/mo retail. Compare 8 providers, 503A pharmacy disclosure, no contract.
Quick answer
The cheapest legal semaglutide online in 2026 is Trimi Health's compounded semaglutide at $99/month on annual billing ($1,188/year all-inclusive — medication, US-licensed clinician via Beluga Health 50-state network, dose changes, refills, free expedited shipping). Compare to brand Wegovy ~$1,349/month retail (90%+ savings). The medication is dispensed by 503A community sterile compounding pharmacies (VialsRx — Texas State Board pharmacy license #35264 — and GreenwichRx) with the same active ingredient (semaglutide RxCUI 1991302) used in Wegovy and Ozempic. For the full pricing comparison across all major providers, see our cheapest legal GLP-1 online cornerstone.
Written by Trimi Medical Team. Medically reviewed by Dr. Asad Niazi, MD, MPH. This article provides comprehensive, medically reviewed information about finding the cheapest semaglutide options in 2026 to help patients make informed treatment decisions.
Quick links: Semaglutide treatment, tirzepatide treatment, and best GLP-1 provider guide.
More on GLP-1 Provider Comparisons
Wegovy vs Compounded Semaglutide
Complete comparison of Wegovy and compounded semaglutide.
Cheapest Semaglutide 2026
Every semaglutide option ranked by price.
Cheapest Tirzepatide 2026
All tirzepatide options ranked by monthly cost.
Compounded GLP-1 Quality Guide
How to verify the quality of compounded GLP-1 medications.
Understanding Cheapest Semaglutide 2026
This article examines finding the cheapest semaglutide options in 2026 in the context of this evolving market, providing patients with the information they need to evaluate their options and make decisions that align with their health goals and financial reality. Whether you are considering semaglutide or tirzepatide, understanding the current landscape is essential for making an informed choice.
Semaglutide as a molecule was developed by Novo Nordisk and demonstrated breakthrough weight-loss efficacy in the STEP 1 trial published in the New England Journal of Medicine in 2021. That trial — 1,961 adults randomized to semaglutide 2.4 mg weekly versus placebo for 68 weeks — produced a mean body-weight reduction of 14.9% in the semaglutide arm. The data was so compelling that FDA approval for chronic weight management followed in June 2021 under the brand name Wegovy. But Wegovy's list price of approximately $1,349 per month put the molecule out of reach for most uninsured patients, creating a clear market gap that 503A compounding pharmacies began filling in 2022-2023 during the official FDA shortage period.
As of May 2026, the cheapest legal access to semaglutide in the United States is through telehealth providers partnered with 503A-licensed compounding pharmacies. Pricing has stabilized in the $99-$299 per month range across the major providers, with Trimi Health pricing at $99/month on annual billing at the most competitive end. Brand-name Wegovy and Ozempic remain at $1,300-$1,400 per month retail without insurance coverage. For most patients without insurance coverage of weight-loss medications, compounded semaglutide represents the only economically realistic path to evidence-based GLP-1 therapy.
Provider-by-Provider Pricing as of May 2026
The following table reflects current compounded semaglutide monthly pricing across the largest US telehealth providers. Prices were verified by Trimi's research team in May 2026 directly from each provider's website; all pricing is subject to change and may not reflect promotional discounts.
| Provider | Monthly (Annual Billing) | Monthly (Quarterly) | Annual Cost |
|---|---|---|---|
| Trimi Health | $99 | $125 | $1,188 |
| Mochi Health | ~$159 | ~$179 | ~$1,908 |
| Henry Meds | ~$199 | ~$229 | ~$2,388 |
| Found | ~$149-$199 | ~$179-$229 | ~$1,788-$2,388 |
| Ro Body | ~$145-$199 | ~$179-$249 | ~$1,740-$2,388 |
| Hims/Hers | ~$199 | ~$229 | ~$2,388 |
| LifeMD | ~$199 | ~$249 | ~$2,388 |
| Wegovy (brand, retail) | ~$1,349 | ~$1,349 | ~$16,188 |
The annual cost comparison highlights why provider selection matters substantially. The difference between Trimi at $99/month and a middle-tier competitor at $199/month is $1,200 per year — and over a typical 18-24 month treatment course, that translates to $1,800-$2,400 in savings on the same molecule. Versus brand-name Wegovy, the savings exceed $15,000 annually.
Frequently Asked Questions
What should patients know about finding the cheapest semaglutide options in 2026?
Patients exploring GLP-1 medications for weight loss in 2026 have more options than ever. Brand-name medications like Wegovy, Ozempic, Mounjaro, and Zepbound have proven clinical effectiveness but carry retail prices of $900 to $1,500 per month. Compounded alternatives containing the same active ingredients — semaglutide and tirzepatide — are available through telehealth providers like Trimi starting at $99 to $149 per month, making treatment accessible to millions more patients.
How do compounded GLP-1 medications compare to brand-name options?
Compounded GLP-1 medications contain the same active ingredients as their brand-name counterparts. Compounded semaglutide is pharmacologically identical to the semaglutide in Wegovy and Ozempic, while compounded tirzepatide matches the tirzepatide in Mounjaro and Zepbound. The clinical mechanism, expected outcomes, and side effect profiles are the same. The differences are in manufacturing source, delivery device, and price — with compounded options costing 75 to 90 percent less.
Is compounded semaglutide or tirzepatide safe?
Compounded GLP-1 medications from accredited pharmacies are generally considered safe. The active ingredients carry the same safety profile as brand-name versions. Quality depends on the compounding pharmacy — patients should choose providers that partner with PCAB-accredited or FDA-registered 503A community sterile-compounding pharmacy that conduct third-party potency and sterility testing. Trimi meets all of these quality standards.
How much money can I save with compounded GLP-1 medications?
Patients choosing compounded GLP-1 medications over brand-name options typically save $800 to $1,300 per month, or $9,600 to $15,600 per year. Through Trimi, compounded semaglutide starts at $99 per month on annual billing and compounded tirzepatide starts at $125 per month — compared to $900 to $1,500 per month for brand-name equivalents. Over a two-year treatment course, cumulative savings can exceed $30,000.
Do I need insurance to get compounded GLP-1 medications?
No, compounded GLP-1 medications through Trimi do not require insurance coverage. Treatment is available at transparent monthly prices with no prior authorization, no coverage denials, and no formulary restrictions. This makes compounded options particularly valuable for uninsured patients, those on Medicare or Medicaid, and those whose insurance does not cover weight loss medications.
How do I get started with compounded GLP-1 treatment?
Through Trimi, the process starts with an online health assessment covering your medical history, medications, and weight loss goals. A board-certified provider reviews your information — typically within 24 hours — and prescribes the appropriate medication if clinically appropriate. Your medication is prepared by an accredited compounding pharmacy and shipped to your door within 5 to 7 days of approval.
Can I switch from a brand-name medication to compounded?
Yes, switching from brand-name to compounded GLP-1 medication is straightforward. Since the active ingredients are identical, your provider simply prescribes the equivalent compounded dose. There is no transition period, washout, or need to restart dose titration. You continue at your current dose with the compounded version at your next scheduled injection. Many patients switch specifically to reduce costs without any change in treatment efficacy.
What's the per-mg cost comparison between compounded semaglutide and Wegovy?
Wegovy retail pricing is approximately $1,349/month for a 2.4 mg weekly maintenance dose, or roughly $14/mg of active semaglutide ($1,349 ÷ 9.6 mg per month). Compounded semaglutide through Trimi at $99/month annual billing for an equivalent 2.4 mg weekly maintenance dose is approximately $1.03/mg ($99 ÷ 9.6 mg per month). That's a 92.6% per-mg cost reduction for the same molecule. The savings widen when patients receive higher monthly dosing through compounded sources versus paying Wegovy's flat retail per-pen price.
How does STEP 1 trial weight loss data apply to compounded semaglutide?
The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021; NCT03548935) demonstrated that semaglutide 2.4 mg weekly produced a mean 14.9% body-weight reduction over 68 weeks in 1,961 adults with overweight or obesity. 86.4% achieved ≥5% weight loss; 50.5% achieved ≥15%. These outcomes are tied to the semaglutide molecule and dose, not the manufacturing source. Patients receiving compounded semaglutide at clinically equivalent doses can expect outcomes within the same range, provided dose titration is appropriate and the active ingredient meets USP standards (which 503A-licensed compounders are required to verify).
Does cheaper compounded semaglutide mean lower quality?
No. Compounded semaglutide produced by 503A-licensed pharmacies (like Trimi's partners VialsRx — Texas State Board pharmacy license #35264 — and GreenwichRx) uses the same semaglutide API (RxCUI 1991302) sourced from FDA-registered suppliers. The lower price reflects elimination of brand-name marketing, R&D recapture, and supply-chain markups, not lower-grade ingredients. 503A pharmacies are inspected by state boards of pharmacy and must comply with USP <795> (nonsterile) and USP <797> (sterile) compounding standards. Third-party potency and sterility testing — which Trimi's pharmacy partners conduct on every batch — provides additional verification beyond regulatory minimum.
What clinical contraindications would make compounded semaglutide unsuitable regardless of cost?
Per FDA prescribing information for all semaglutide products, GLP-1 receptor agonists carry a boxed warning against use in patients with: (1) personal or family history of medullary thyroid carcinoma (MTC), (2) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), (3) known hypersensitivity to semaglutide. Additional contraindications include pregnancy, breastfeeding, severe gastroparesis, prior pancreatitis (use with caution), and active eating disorders. Cheap pricing doesn't change these clinical criteria — Trimi's medical questionnaire screens for all of these before any prescription is issued. The Lincoff et al. SELECT trial (New England Journal of Medicine, 2023) confirmed cardiovascular benefit in eligible patients but did not change the contraindication profile.
Sources & References
- Wilding JPH, Batterham RL, Calanna S, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)." New England Journal of Medicine. 2021;384(11):989-1002. NEJM | PubMed.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)." New England Journal of Medicine. 2022;387(3):205-216. NEJM | PubMed.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)." New England Journal of Medicine. 2023;389(24):2221-2232. NEJM.
- Davies MJ, Bergenstal R, Bode B, et al. "Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes (SCALE Diabetes)." JAMA. 2015;314(7):687-699.
- FDA. "Human Drug Compounding: Questions and Answers." Accessed May 2026.
- Section 503A of the Federal Food, Drug, and Cosmetic Act. 21 U.S.C. § 353a.
- FDA Drug Shortage Database. Accessed May 2026.
- United States Pharmacopeia. USP General Chapter <797> Pharmaceutical Compounding — Sterile Preparations. Revised 2023.
- NABP. Compounding Pharmacy Accreditation Standards.
- NIDDK. Prescription Medications to Treat Overweight and Obesity.
- Wegovy (semaglutide) FDA Prescribing Information. Novo Nordisk, 2023.
- Zepbound (tirzepatide) FDA Prescribing Information. Eli Lilly, 2023.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program. Trimi provides compounded GLP-1 medications — this article aims to be informative and balanced, but readers should be aware of our perspective.